Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Therapy

Wager of war on bromodomains

Nature Reviews Cancer volume 11, page 760 (2011)Cite this article

Subjects

Access through your institution
Buy or subscribe

Dawson and colleagues showed that mixed-lineage leukaemia (MLL) fusion proteins, which commonly occur in aggressive leukaemia, associate with the bromodomain and extraterminal (BET) family of chromatin adaptor proteins. So, to target MLL-fusion-induced transcriptional responses, the authors treated mouse and human MLL-fusion leukaemia cells with a BET inhibitor, GSK1210151A, which induced cell cycle arrest and apoptosis. GSK1210151A treatment altered the expression of a common set of genes; in particular, BCL2, MYC and cyclin-dependent kinase 6 (CDK6) expression was reduced. The drug also improved the survival of mice with leukaemia induced by the expression of MLL-AF9 or MLL-AF4. In another paper, Mertz and colleagues treated various leukaemia and lymphoma cell lines with the BET inhibitor JQ1, which suppressed MYC expression and altered the expression of MYC target genes. Treatment with JQ1 resulted in cell cycle arrest and apoptosis, which was suppressed by exogenous expression of MYC from a BET regulation-resistant promoter. Finally, JQ1 reduced tumour growth of Burkitt's lymphoma cell and acute myeloid leukaemia cell xenografts. Together, these and the other recent papers that have investigated targeting the BET family indicate that this could be an efficacious strategy for targeting several types of leukaemia and, potentially, tumours overexpressing MYC.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPERS

  1. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2 Oct 2011 (doi:10.1038/nature10509)

  2. Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 26 Sep 2011 (doi:10.1073/pnas.1108190108)

Download references

Authors
  1. Gemma Alderton
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alderton, G. Wager of war on bromodomains. Nat Rev Cancer 11, 760 (2011). https://doi.org/10.1038/nrc3163

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrc3163

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing